Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images
NCT ID: NCT05573815
Last Updated: 2022-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
558 participants
INTERVENTIONAL
2022-09-16
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The specific aims of this study are to evaluate efficacy of BT-M01 for brain metastasis compared to the sensitivity and false positive rates of radiologists group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
NCT06092125
Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of Central Nervous System (CNS) Metastases
NCT04700748
Translocator Protein PET/CT in Various TSPO-Related Disease
NCT06725719
Brain Diseases on 7.0T Magnetic Resonance Imaging
NCT05287750
Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T.
NCT00184353
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Positive group
A patient diagnosed with brain metastasis after a brain MR
BT-M01
Clinical decision support system for detecting brain metastasis
Negative group
A normal person or a patient not diagnosed with brain metastasis after a brain MR
BT-M01
Clinical decision support system for detecting brain metastasis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BT-M01
Clinical decision support system for detecting brain metastasis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Brain MR acquired
* Positive group: A patient diagnosed with brain metastasis after a brain MR
* Negative group: A normal person or a patient not diagnosed with brain metastasis after a brain MR
Exclusion Criteria
* A patient with other pathological lesion in brain
* A patients with a history of primary brain tumors
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heuron Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ji Eun Park, M.D.pH.D
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, Song-pa Gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HR-BM-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.